Moderna and Merck Melanoma Vaccine Trial Results
The Pure Report account · 3 sources · as of Aug 20, 12:46 UTC
Moderna and Merck announced a trial showing mRNA therapy significantly cuts odds of recurrent skin cancer. The Phase 3 trial included 1,137 patients who had stage IIB–IV melanoma.
What we know
- Moderna and Merck announced a trial showing mRNA therapy significantly cuts odds of recurrent skin cancer.
receipt
“Moderna and Merck announce ‘landmark’ trial showing mRNA therapy significantly cuts odds of recurrent skin cancer” — verbatim from Scientific American · article
Framing spectrum · 4 outlets
Coverage patterns
Earliest report in our feed set (publisher timestamps): Ars Technica, Aug 19, 16:53 UTC.
| Lean | Outlets | Articles | Who |
|---|---|---|---|
| Center | 1 | 1 | Al Jazeera English |
| Right | 1 | 1 | Fox News |
| Unclassified | 2 | 2 | Ars Technica, Scientific American |
Report-by-report timeline · 4
Coverage patterns reflect only the ~50 feeds Pure Report ingests — not the full media universe. Timestamps are publisher-reported. Lean labels are Pure Report's classification. Articles are grouped by automated clustering, and counts include syndicated wire copies.